Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

Structural and functional characterization of Reston Ebola virus VP35 interferon inhibitory domain.

Leung DW, Shabman RS, Farahbakhsh M, Prins KC, Borek DM, Wang T, M├╝hlberger E, Basler CF, Amarasinghe GK.

J Mol Biol. 2010 Jun 11;399(3):347-57. doi: 10.1016/j.jmb.2010.04.022. Epub 2010 Apr 24.

2.

Differential Regulation of Interferon Responses by Ebola and Marburg Virus VP35 Proteins.

Edwards MR, Liu G, Mire CE, Sureshchandra S, Luthra P, Yen B, Shabman RS, Leung DW, Messaoudi I, Geisbert TW, Amarasinghe GK, Basler CF.

Cell Rep. 2016 Feb 23;14(7):1632-1640. doi: 10.1016/j.celrep.2016.01.049. Epub 2016 Feb 11.

3.

Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35.

Leung DW, Prins KC, Borek DM, Farahbakhsh M, Tufariello JM, Ramanan P, Nix JC, Helgeson LA, Otwinowski Z, Honzatko RB, Basler CF, Amarasinghe GK.

Nat Struct Mol Biol. 2010 Feb;17(2):165-72. doi: 10.1038/nsmb.1765. Epub 2010 Jan 17.

4.

Crystallization and preliminary X-ray analysis of Ebola VP35 interferon inhibitory domain mutant proteins.

Leung DW, Borek D, Farahbakhsh M, Ramanan P, Nix JC, Wang T, Prins KC, Otwinowski Z, Honzatko RB, Helgeson LA, Basler CF, Amarasinghe GK.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2010 Jun 1;66(Pt 6):689-92. doi: 10.1107/S1744309110013266. Epub 2010 May 27.

5.

Marburg virus VP35 can both fully coat the backbone and cap the ends of dsRNA for interferon antagonism.

Bale S, Julien JP, Bornholdt ZA, Kimberlin CR, Halfmann P, Zandonatti MA, Kunert J, Kroon GJ, Kawaoka Y, MacRae IJ, Wilson IA, Saphire EO.

PLoS Pathog. 2012 Sep;8(9):e1002916. doi: 10.1371/journal.ppat.1002916. Epub 2012 Sep 13.

6.

Structural basis for Marburg virus VP35-mediated immune evasion mechanisms.

Ramanan P, Edwards MR, Shabman RS, Leung DW, Endlich-Frazier AC, Borek DM, Otwinowski Z, Liu G, Huh J, Basler CF, Amarasinghe GK.

Proc Natl Acad Sci U S A. 2012 Dec 11;109(50):20661-6. doi: 10.1073/pnas.1213559109. Epub 2012 Nov 26.

7.

Structure of the Ebola VP35 interferon inhibitory domain.

Leung DW, Ginder ND, Fulton DB, Nix J, Basler CF, Honzatko RB, Amarasinghe GK.

Proc Natl Acad Sci U S A. 2009 Jan 13;106(2):411-6. doi: 10.1073/pnas.0807854106. Epub 2009 Jan 2.

8.

Development of RNA aptamers targeting Ebola virus VP35.

Binning JM, Wang T, Luthra P, Shabman RS, Borek DM, Liu G, Xu W, Leung DW, Basler CF, Amarasinghe GK.

Biochemistry. 2013 Nov 26;52(47):8406-19. doi: 10.1021/bi400704d. Epub 2013 Nov 14.

9.

Mutations abrogating VP35 interaction with double-stranded RNA render Ebola virus avirulent in guinea pigs.

Prins KC, Delpeut S, Leung DW, Reynard O, Volchkova VA, Reid SP, Ramanan P, Cárdenas WB, Amarasinghe GK, Volchkov VE, Basler CF.

J Virol. 2010 Mar;84(6):3004-15. doi: 10.1128/JVI.02459-09. Epub 2010 Jan 13.

10.

Ebolavirus VP35 is a multifunctional virulence factor.

Leung DW, Prins KC, Basler CF, Amarasinghe GK.

Virulence. 2010 Nov-Dec;1(6):526-31. Epub 2010 Nov 1.

11.

Exploration micromechanism of VP35 IID interaction and recognition dsRNA: A molecular dynamics simulation.

Zhang YJ, Ding JN, Zhong H, Han JG.

Proteins. 2017 Jun;85(6):1008-1023. doi: 10.1002/prot.25269. Epub 2017 Mar 7.

PMID:
28205249
12.

Crystal Structure of the Marburg Virus VP35 Oligomerization Domain.

Bruhn JF, Kirchdoerfer RN, Urata SM, Li S, Tickle IJ, Bricogne G, Saphire EO.

J Virol. 2017 Jan 3;91(2). pii: e01085-16. doi: 10.1128/JVI.01085-16. Print 2017 Jan 15.

13.

dsRNA binding characterization of full length recombinant wild type and mutants Zaire ebolavirus VP35.

Zinzula L, Esposito F, Pala D, Tramontano E.

Antiviral Res. 2012 Mar;93(3):354-63. doi: 10.1016/j.antiviral.2012.01.005. Epub 2012 Jan 25.

PMID:
22289166
14.

Basic residues within the ebolavirus VP35 protein are required for its viral polymerase cofactor function.

Prins KC, Binning JM, Shabman RS, Leung DW, Amarasinghe GK, Basler CF.

J Virol. 2010 Oct;84(20):10581-91. doi: 10.1128/JVI.00925-10. Epub 2010 Aug 4.

15.

DRBP76 associates with Ebola virus VP35 and suppresses viral polymerase function.

Shabman RS, Leung DW, Johnson J, Glennon N, Gulcicek EE, Stone KL, Leung L, Hensley L, Amarasinghe GK, Basler CF.

J Infect Dis. 2011 Nov;204 Suppl 3:S911-8. doi: 10.1093/infdis/jir343.

16.

Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression.

Kimberlin CR, Bornholdt ZA, Li S, Woods VL Jr, MacRae IJ, Saphire EO.

Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):314-9. doi: 10.1073/pnas.0910547107. Epub 2009 Dec 14.

17.

In silico derived small molecules bind the filovirus VP35 protein and inhibit its polymerase cofactor activity.

Brown CS, Lee MS, Leung DW, Wang T, Xu W, Luthra P, Anantpadma M, Shabman RS, Melito LM, MacMillan KS, Borek DM, Otwinowski Z, Ramanan P, Stubbs AJ, Peterson DS, Binning JM, Tonelli M, Olson MA, Davey RA, Ready JM, Basler CF, Amarasinghe GK.

J Mol Biol. 2014 May 15;426(10):2045-58. doi: 10.1016/j.jmb.2014.01.010. Epub 2014 Feb 1.

18.

Expression, purification, crystallization and preliminary X-ray studies of the Ebola VP35 interferon inhibitory domain.

Leung DW, Ginder ND, Nix JC, Basler CF, Honzatko RB, Amarasinghe GK.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2009 Feb 1;65(Pt 2):163-5. doi: 10.1107/S1744309108044187. Epub 2009 Jan 31.

19.
20.

Current knowledge on lower virulence of Reston Ebola virus (in French: Connaissances actuelles sur la moindre virulence du virus Ebola Reston).

Morikawa S, Saijo M, Kurane I.

Comp Immunol Microbiol Infect Dis. 2007 Sep;30(5-6):391-8. Epub 2007 Jul 3. Review.

PMID:
17610952

Supplemental Content

Support Center